CD44 positive and sorafenib insensitive hepatocellular carcinomas respond to the ATP-competitive mTOR inhibitor INK128

The mTOR pathway is activated in about 50% of patients with hepatocellular carcinoma (HCC). In an effort to identify new pathways and compounds to treat advanced HCC, we considered the ATP-competitive mTOR inhibitor INK128. ATP-competitive mTOR inhibitors attenuate both mTORC1 and mTORC2. INK128 was...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncotarget
Päätekijät: Badawi, Mohamed, Kim, Jihye, Dauki, Anees, Sutaria, Dhruvitkumar, Motiwala, Tasneem, Reyes, Ryan, Wani, Nissar, Kolli, Shamalatha, Jiang, Jinmai, Coss, Christopher C., Jacob, Samson T., Phelps, Mitch A., Schmittgen, Thomas D.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Impact Journals LLC 2018
Aiheet:
Research Paper
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5995255/
https://ncbi.nlm.nih.gov/pubmed/29899840
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25430
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia